Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-08-16
2011-08-16
Stucker, Jeffrey (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S135100, C424S139100, C424S141100, C424S142100, C424S145100, C435S328000, C435S331000, C435S336000, C435S358000, C435S975000
Reexamination Certificate
active
07998480
ABSTRACT:
The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies and therapeutic compositions containing said antibodies.
REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4510245 (1985-04-01), Cousens et al.
patent: 4607023 (1986-08-01), Thibault et al.
patent: 4634665 (1987-01-01), Axel et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4968615 (1990-11-01), Koszinowski et al.
patent: 5114923 (1992-05-01), Seilhamer et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5179017 (1993-01-01), Axel et al.
patent: 5468646 (1995-11-01), Mattingly et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5674710 (1997-10-01), Seilhamer et al.
patent: 6090382 (2000-07-01), Salfeld et al.
patent: 6117644 (2000-09-01), DeBold
patent: 6124430 (2000-09-01), Mischak et al.
patent: 6162902 (2000-12-01), Mischak et al.
patent: 6376207 (2002-04-01), Mischak et al.
patent: 6461828 (2002-10-01), Stanton et al.
patent: 6677124 (2004-01-01), Tsuji et al.
patent: 6770740 (2004-08-01), Rice et al.
patent: 7341838 (2008-03-01), Buechler et al.
patent: 7351586 (2008-04-01), Friese et al.
patent: 2003/0022235 (2003-01-01), Dahlen et al.
patent: 2003/0162710 (2003-08-01), Sudoh et al.
patent: 2003/0199000 (2003-10-01), Valkirs et al.
patent: 2003/0229207 (2003-12-01), Studnicka
patent: 2004/0132013 (2004-07-01), De Bold
patent: 2004/0175379 (2004-09-01), DeVries et al.
patent: 2004/0180396 (2004-09-01), Bergmann et al.
patent: 2004/0209307 (2004-10-01), Valkirs et al.
patent: 2004/0219509 (2004-11-01), Valkirs et al.
patent: 2004/0243010 (2004-12-01), Zoghbi et al.
patent: 2004/0253655 (2004-12-01), Tsuji et al.
patent: 2004/0265926 (2004-12-01), Ng
patent: 2005/0014287 (2005-01-01), Friese et al.
patent: 2005/0064511 (2005-03-01), Buechler et al.
patent: 2006/0121042 (2006-06-01), Dall'Acqua et al.
patent: 2006/0121242 (2006-06-01), Pesovic et al.
patent: 2006/0183154 (2006-08-01), Shih et al.
patent: 2007/0207152 (2007-09-01), Brophy et al.
patent: 0 384 176 (1990-08-01), None
patent: 0 418 308 (1991-03-01), None
patent: 0 542 255 (1993-05-01), None
patent: 0 914 344 (1999-05-01), None
patent: 1 016 867 (2000-07-01), None
patent: 1 030 177 (2000-08-01), None
patent: 3297392 (1991-12-01), None
patent: 2676114 (1997-11-01), None
patent: 2004/094460 (2004-11-01), None
patent: 2007056507 (2007-05-01), None
Colucci, et al., “Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure”, N. Engl. Med., 2000, 343 (34), pp. 246-253.
PCT International Application No. PCT/US2006/0043608; Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, mailed Mar. 27, 2007 (13 pages).
Thorpe, et al., “Enhanced Chemiluminescent Reactions Catalyzed by Horseradish Peroxidase,” Methods in Enzymology, 1986, 133, pp. 333-353.
Tsutamoto, et al., “Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure,” 1997, 96, pp. 509-516.
PCT International Application No. PCT/US2008/062973, Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, mailed Sep. 2, 2008.
Abbott AXYSM® System, BNP package insert, REF 8G82-20 Abbott Diagnostics Division, Feb. 2004.
Apple, et al., “Quality Specifications for B-Type Natriuretic Peptide Assays,”Clin. Chem., 51(3):486-493 (2005).
Ausubel, et al.,Curr. Protocols in Molec. Biol., Section 2.10 (Terry Brown) and Section 6.3 (William W. Strauss) (1997).
Belenky, et al., “The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma,”Clinica Chimica Acta, 340:163-172 (2004).
Benjamini, et al.,S., Immunology, A Short Course, Immunogens and Antigens, 2ndEd., pp. 37-40 (1991).
Berzofsky, et al., “Antigen-Antibody Interactions and Monoclonal Antibodies,”Fund. Immunol., 2:315-336 (1989).
Bird, et al., “Single-Chain Antigen-Binding Proteins,”Science, 242:423-426 (1988).
Bluestein, “Comparing BNP ASSAYS, Factors Impacting Analytical Method Comparison,”Bayer Healthcare Diagnostics Division Publ., (2004).
Boder, et al., “Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity,”PNAS, 97(20): 10701-10705, (2000).
Boder, et al., “Optimal Screening of Surface-Displayed Polypeptide Libraries,”Biotechnol. Prog., 14:55-62 (1998).
Boder, et al., “Yeast Surface Display for Directed Evolution of Protein Expression, Affinity, and Stability,”Meth. in Enzymol., 328:430-444 (2000).
Boder, et al., “Yeast surface display for screening combinatorial polypeptide libraries,”Nature Biotech., 15(6):553-557 (1997).
Bogan, et al., “Anatomy of Hot Spots in Protein Interfaces,”J. Mol. Biol., 280:1-9 (1998).
Boss, et al., “Genetically engineered antibodies,”Imunol. Today, 6(1):12-13 (1985).
Brandt, et al., “Dipeptidyl-Peptidase IV Converts Intact B- Type Natriuretic Peptide into Itsdes-SerPro Form,”Clin. Chem., 52(1):82-87 (2006).
Buckley, et al., “Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice,”Clin. Sci., 97:689-695 (1999).
Cataliotti, et al., “Circulating Natriuretic Peptide Concentrations in Patients with End-Stage Renal Disease: Role of Brain Natriuretic Peptide as a Biomarker for Ventricular Remodeling,”Mayo Clin. Proc., 76:1111-1119 (2001).
Davidson, et al., “Brain natriuretic peptide,”J. of Hypertension, 12:329-336 (1994).
Diagnostic Automation/Cortez Diagnostics, Inc., “Nt-proBNP ELISA Quantitative dertermination of Nt-proBNP in biological fluids,” (Cat. No. 2852-7), pp. 1-8 (1997).
Galfre, et al., “Antibodies to major histocompatibility antigens produced by hybrid cell lines,”Nature, 266:550-552 (1977).
Gutkowska, et al., “Atrial Natriuretic Factor in Human Plasma,”Biochem.&Biophys. Res. Comm., 139(1):287-295 (1986).
Holmes, et al., “Renal, Endocrine, and Hemodynamic Effects of Human Brain Natriuretic Peptide in Normal Man,”J. of Clin. Endocrin.&Metab., 76(1):91-96 (1993).
Huston, et al., “Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli,” PNAS, 85:5879-5883 (1988).
Itoh, et al., “Preparation of Monoclonal Antibodies against Brain Natriuretic Peptide and Their Application to Radioimmunoassay and Passive Immunization,”Endocrinology, 127(3):1292-1300 (1990).
Kabat, et al., “Sequences of Proteins of Immun. Interest,”U.S. Dept. of Health&Human Serv., NIH Publ. 91/3242, 5th:Tb1 of Cont., (1991).
Kaufman, et al, “Amplification and Expression of Sequences cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene,”J. Mol. Biol., 159:601-621 (1982).
Kenny, et al., “Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11,”Biochem. J., 291:83-88 (1993).
Ma, et al., “Protein-protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces,”PNAS, 100(10):5772-5777 (2003).
McCafferty, et al., “Phage antibodies: filamentous phage displaying antibody variable domains,”Nature, 348:552-554 (1990).
Mizushima, et al., “pEF-BOS, a powerful mammalian expression vector,”Nucl. Acids Res., 18(17):5322 (1990).
Morrison, et al., “Chimeric human
Brophy Susan E.
Pinkus Mary S.
Shih Jessie W.
Tieman Bryan C.
Tu Bailin X.
Abbott Laboratories
Bartnicki Audrey L
Gucker Stephen
Mueller Lisa V.
Polsinelli Shughart
LandOfFree
Human BNP immunospecific antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human BNP immunospecific antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human BNP immunospecific antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2637819